MHRA approves Marinus’ ganaxolone for CDKL5 deficiency disorderCDKL5 deficiency disorder
08 Mar 2024
Phase 3Drug ApprovalClinical Result
Preview
Source: Pharmaceutical Technology
The approval of ganaxolone is based on results from a Phase III clinical trial in subjects aged two to 19 years. Credit: LightField Studios / Shutterstock.com.
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Marinus Pharmaceuticals Emerald’s ganaxolone, marketed as Ztalmy, an anti-seizure medication for cyclin-dependent kinase-like 5 (CDLK5) deficiency disorder (CDD)cyclin-dependent kinase-like 5 (CDLK5) deficiency disorder (CDD).
CDD is a rare genetic ailment characterised by early-onset seizures and severe developmental delays due to mutations in the CDLK5 gene, essential for normal brain development.
Ganaxolone, administered orally via a dosing syringe, is a steroid that targets specific brain receptors to prevent epileptic seizures.
The approval of ganaxolone is based on results from a Phase III clinical trial.
The double-blind placebo-controlled study involved 101 subjects aged two to 19 years.
See Also:
BeiGene secures accelerated FDA approval for follicular lymphoma treatment
Preview
Source: Pharmaceutical Technology
FDA approves BMS’ Opdivo for urothelial carcinoma
Preview
Source: Pharmaceutical Technology
The subjects were randomised with 50 receiving ganaxolone and 51 a placebo over 17 weeks.
Those treated with ganaxolone showed a significant reduction in 28-day seizure frequency, averaging almost 30%, versus a 6.5% reduction for those on the placebo at 13 weeks.
Side effects linked to ganaxolone are drowsiness or sleepiness and fever.
The MHRA will monitor the safety and efficacy of the drug.
Individuals experiencing adverse effects are encouraged to consult their healthcare provider and report the incident through the MHRA Yellow Card scheme, accessible online or via mobile app stores.
MHRA Healthcare Quality and Access interim executive director Julian Beach stated: “Keeping patients safe and enabling their access to high quality, safe and effective medical products are key priorities for us.
“We’re assured that the appropriate regulatory standards for the approval of this medicine have been met.
“As with all medicines, we will keep its safety under close review.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.